클래시스

214150KOSDAQ의료용 기기 제조업

60.4 / 100

Reference Date: 2026-07-24

Financial Score20.5 / 40

News Sentiment19.9 / 25

Momentum5.0 / 20

Disclosure15.0 / 15

AI Analysis: ROE significantly exceeds the industry average but PBR raises overvaluation concerns. Slightly down 2.8% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Classys operates three main brands (CLASSYS, Cluederm, and ShringkRX/Skedum), focusing on aesthetic medical devices, consumables, and cosmetics. The company merged with IruDa in October 2024, enhancing its technological competitiveness in key EBD segments like micro-needle RF and laser. It generates revenue from over 80 countries, with medical devices and consumables accounting for 46% and 45% of sales, respectively.

Number of Employees

528people

Average Salary

65.1M KRW

Score Calculation Basis

Detailed Financial Score

PER

21.94Industry Average 20.043.0Point

Higher than industry avg (caution)

PBR

5.23Industry Average 1.140.0Point

4.6x industry avg (risky)

ROE

26.28Industry Average 8.007.0Point

3.3x industry avg (excellent)

Debt Ratio

13.19Industry Average 11.652.0Point

Higher than industry avg (caution)

Trend 2023~20258.5 / 10 points

Revenue Growth Rate

3.0 / 3

Avg ▲36.8% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲38.0% (2-year basis)

ROE Trend

2.5 / 4

Avg ROE 27.2% (declining, 3yr)

Detailed News Sentiment

9 totalPositive 7Neutral 0Negative 2Average Sentiment Score 79.4

Negative
[클릭 e종목]"클래시스, 단기 눈높이 재조정 필요…목표가↓"
삼성증권의 클래시스 목표주가 하향 조정으로 인해 단기 투자 전망이 부정적으로 평가됨.
Positive
'하만 인수 주역' 윤준오 前삼성전자 부사장, 클래시스 대표로
윤준오 전 삼성전자 부사장의 클래시스 대표 선임은 기업의 전략적 경험과 전문성을 바탕으로 회사의 성장 가능성을 높이는 긍정적 신호입니다.
Negative
클래시스, 견조한 해외 대비 아쉬운 국내 성장세…목표가 19%↓-키움
국내 시장 성장 부진으로 키움증권이 클래시스의 목표주가를 하향 조정했다.

Detailed Momentum

52-week position1.0Point

Near 52w low (4%, downtrend)

Current 44,250Won52-week high 75,60052-week low 42,650

1-month return2.0Point

1m -2.75% (slight drop)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

6 totalPositive 3Neutral 3Negative 0

Neutral주식등의대량보유상황보고서(약식)2026-07-16
Neutral대표집행임원변경2026-07-15
Neutral주식매수선택권부여에관한신고2026-07-15
Positive최대주주변경을수반하는주식담보제공계약체결2026-06-26
Positive최대주주변경을수반하는주식담보제공계약체결2026-06-26